This protocol reviews the appropriate use of serum testosterone testing in men and women aged ≥ 19 years. This document is intended to direct primary care practitioners and to help constrain inappropriate test utilization, particularly as it pertains to "wellness" and "anti-aging" practices. This protocol expands on the guidance provided in the associated BC Guideline.caHormone Testing -Indications and Appropriate Use. Testosterone testing for pediatric and transgender * patients is out of scope of this protocol.
• In men, serum total testosterone must be collected in the morning, preferably before 10AM, or within 3 hours of waking, and preferably in a fasting state.
• Men receiving stable androgen replacement can be tested annually.
• Testosterone testing is not useful for the investigation of low libido in women.
Tests
The testosterone tests available in British Columbia are:
• serum total testosterone
• calculated bioavailable testosterone (cBAT), which includes the sex hormone binding globulin test (SHBG) Circulating testosterone exists in three forms: free, weakly bound to albumin, and strongly bound to SHBG. Serum total testosterone measures all three forms. Bioavailable testosterone is the sum of free testosterone and albumin bound testosterone. In BC, all bioavailable and free testosterone results are calculated rather than directly measured. Calculated bioavailable testosterone (cBAT) and calculated free testosterone are derived from the same calculation, which utilizes both the measured total testosterone and measured SHBG concentrations. Although the two parameters may be reported separately, cBAT and calculated free testosterone are functionally and diagnostically equivalent (and therefore redundant) -as such, only cBAT will be referenced in the remainder of the guideline. Reference ranges for serum total testosterone and cBAT are method and age dependent and are determined by each laboratory independently.
Patients should use the same lab for initial and follow up testosterone tests because reference ranges are lab-dependent, 
Testosterone Deficiency in Men
Routine biochemical screening for testosterone deficiency (hypogonadism) in asymptomatic men is not recommended. A decision to test must be guided by the medical history and clinical examination. In the case of isolated, or non-specific symptoms only, a comprehensive general assessment is required to exclude potential alternative explanations 3 and to guide further investigations. In the case of follow up of a previously ordered, relatively low, testosterone measurement, in a minimally symptomatic man, refer to Appendix A: Differential Diagnosis of Hypogonadism in Men and Appendix B: Medications that May Alter Testosterone Levels in Men and Women for conditions and medications associated with changes in testosterone concentration.
Signs and Symptoms of Testosterone Deficiency in Men
There are many non-specific somatic and psychological symptoms associated with hypogonadism (refer to Table 1 below) . Any one finding alone is insufficient grounds to order a testosterone test.
Late-onset (age ≥ 40 years) hypogonadism is most specifically defined by the presence of at least three sexual symptoms (decreased frequency of morning erection, decreased frequency of sexual thoughts, and erectile dysfunction) associated with low testosterone and/or a low cBAT. 3 Erectile dysfunction in isolation is not an indication for testosterone testing because the prevalence of hypogonadism among patients with erectile dysfunction is low. Some symptoms of hypogonadism in men ≥ 40 years overlap with normal effects of aging. 7 The documentation of low total testosterone in elderly men with non-specific symptoms of hypogonadism does not necessarily imply that low testosterone is the cause.
Testing for Testosterone Deficiency in Men
Serum total testosterone is the initial test of choice. Specimens must be collected in the morning, 8 preferably before 10AM, or within 3 hours of waking, and preferably in a fasting state 5, 9 . Testing should occur when the sleep-wake pattern is stable (e.g., not during shift changes or jetlag). Testing of serum total testosterone should be performed when patients are clinically well; do not test during acute illness or hospitalization.
If the total testosterone level is below the lab-specific lower limit of normal (approximately 8 nmol/L in younger men (<30 years), and 6 nmol/L in older men (> 50 years)), [10] [11] [12] [13] and a diagnostic question remains, cBAT (which includes SHBG) can be used to confirm or rule out hypogonadism.
For men, total testosterone levels may be low but the cBAT normal when the SHBG concentration is decreased. Total testosterone levels may be normal but cBAT low when SHBG concentration is increased. Idiopathic elevations in SHBG are well known as are other conditions that are associated with mild to marked changes in the SHBG concentration. Refer to
Appendix C: Conditions Associated with Altered SHBG Concentrations in Men and Women.
Note that testosterone is characterized by episodic secretion: 30% of men with mildly hypogonadal serum testosterone levels will have a normal level on retesting.
Diagnosis in Men
It has been observed that men in BC frequently receive prescriptions for testosterone replacement without first having a serum testosterone test to confirm low levels.
14 This practice is not appropriate, as biochemical confirmation of a low for age serum total testosterone (or cBAT) is necessary to confirm the clinical impression of hypogonadism. In the absence of this biochemical confirmation, a re-visitation or verification of the original empiric diagnosis will be very difficult since prolonged androgen therapy will result in suppression of the hypothalamic pituitary gonadal axis for as long as 18 months.
While specific investigation is beyond the scope of this protocol, it is important to establish the etiology of hypogonadism, after biochemical confirmation of the clinical diagnosis, and before initiating testosterone replacement. Refer to Appendix A: Differential Diagnosis of Hypogonadism in Men and Appendix D: Hypogonadism Investigation Algorithm for guidance on initial investigation and testing.
Prior to initiating testosterone replacement, the following baseline tests are recommended: hematocrit, prostate-specific antigen (PSA), and digital rectal exam (DRE). 7 Other contraindications to testosterone replacement should be considered. These are discussed in detail elsewhere. 5, 7 Occasionally the cause of hypogonadism is congenital/pituitary/hypothalamic in nature and if there are pre-existing risk factors (e.g., cranial irradiation, hemochromatosis), referral to endocrinology is recommended. Refer to Appendix D: Hypogonadism Investigation Algorithm for more information.
Consider referral if uncertain. Indications for referral to specialists are outlined in Table 2 below.
Occasionally it is discovered that a man has a high total testosterone. This can be investigated by ordering SHBG. Note, however, that current MSP billing rules require pathologist approval prior to ordering an SHBG test on a patient with a relatively high total testosterone concentration.
Monitoring of Testosterone-Replacement Treatment in Men
Monitor men receiving androgen replacement by repeating the hematocrit, PSA test, and DRE at 3 and 6 months after initiation, then annually if stable. 7 Some recommend that PSA testing after one year is not necessarily obligatory. 5 Men receiving stable androgen replacement can be tested with serum total testosterone testing annually. 5, 7 Blood collection timing by route of administration: 5 • Injectable testosterone enanthate or cypionate: measure testosterone midway between injections • Transdermal gels/Intranasal: measure 2-8 hours after application • Transdermal patches: 3-12 hours after application • Oral testosterone undecanoate: 3-5 hours after ingestion with a fat-containing meal
Testosterone Testing in Prostate Cancer
Total testosterone testing is indicated to confirm adequacy of androgen deprivation therapy (ADT) in men with prostate carcinoma. Only tandem mass spectrometry is sufficiently sensitive to accurately measure the low total testosterone seen in men rendered chemically castrate for treatment of prostate carcinoma. 15 In BC, testosterone analysis by tandem mass spectrometry is not routinely available and should be specifically requested on the requisition. Testosterone should be tested 3 months after initiating ADT, and in the event of any increase in PSA levels.
Testosterone Analysis in Women
Testosterone testing is indicated for investigation of signs and symptoms of hyperandrogenism in women based on medical history and clinical examination. Testosterone testing is not indicated for the investigation of women with low libido. 16 The upper limit of normal for testosterone in women is approximately 2-3 nmol/L, or slightly higher depending on menstrual phase and use of oral contraceptive medications. 17 In polycystic ovarian syndrome, total testosterone concentrations are within the normal reference interval or slightly higher. Consequently, testosterone concentrations greater than twice the upper limit of normal (i.e., greater than 5 nmol/L) suggest an alternate etiology, such as an androgen-secreting tumour.
Signs and Symptoms of Hyperandrogenism in Women
A range of symptoms and signs from hirsutism to virilisation may occur. The Endocrine Society recommends testing for hyperandrogenism in women with hirsutism that is moderate or severe, of rapid onset, or accompanied by menstrual dysfunction, obesity or clitoromegaly. 18 Other indications for referral are outlined at the end of this document.
Testing for Hyperandrogenism in Women
Serum total testosterone is frequently normal in women with mild clinical hyperandrogenism (due to androgen suppression of SHBG production). cBAT testing (which includes SHBG) has a better diagnostic yield for testosterone excess in women. 19 Repeat serum testosterone testing is not indicated if cBAT is normal. Testing of other androgens is dependent on clinical findings and is beyond the scope of this protocol; for more information refer to the BC Guideline.ca -Hormone TestingIndications and Appropriate Use. For women who have regular menstrual cycles, collection should be performed in the morning on day 4-10.
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Diagnosis of the Cause of Hyperandrogenism in Women
The diagnosis of testosterone excess is based on medical history and physical findings, followed by investigational tests.
The most common cause of hirsutism 20 and of excess androgen production in pre-menopausal women 18 is polycystic ovary syndrome (PCOS). It is important to rule out non-classic congenital adrenal hyperplasia, which occurs in 1.5-6.8% of women with hyperandrogenism. 21 A history of rapid virilization is suggestive of ovarian or adrenal malignancy and such patients should be immediately referred. Table 2 below.
Monitoring Response to Treatment in Women
Women receiving treatment for hyperandrogenism: Response to treatment of hyperandrogenism in women is clinical. Therefore, testing serum total testosterone and cBAT in patients treated for hyperandrogenism is not recommended unless a concrete cause has been identified, such as non-classical congenital adrenal hyperplasia or an androgen-secreting tumour.
Women receiving androgen therapy for low libido: Testosterone testing is not useful for monitoring women receiving androgen therapy for low libido unless overuse is suspected or unexpected virilisation has developed. • Pathways -PathwaysBC.ca An online resource that allows GPs and nurse practitioners and their office staff to quickly access current and accurate referral information, including wait times and areas of expertise, for specialists and specialty clinics. In addition, Pathways makes available hundreds of patient and physician resources that are categorized and searchable. 
Indications for Referral
Patient and Caregiver Resources
Disclaimer
The Clinical Practice Guidelines (the "Guidelines") have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problem. We cannot respond to patients or patient advocates requesting advice on issues related to medical conditions. If you need medical advice, please contact a health care professional.
THE GUIDELINES AND PROTOCOLS ADVISORY COMMITTEE
This guideline is based on scientific evidence current as of the Effective Date.
The guideline was developed by the Guidelines and Protocols Advisory Committee in collaboration with BC's Agency for Pathology and Laboratory Medicine, and adopted by the Medical Services Commission.
Investigate for other causes of the non specific symptoms
Measure morning fasting total testosterone (TT)
History and physcial exam*
